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Abstract
In solid organ transplant (SOT) recipients it is unknown if natural infection with influenza confers protection from re-
infection with the same strain during the next influenza season. The purpose of this study was to determine if infection with
pandemic influenza A/H1N1 (pH1N1) resulted in a long-term immunologic response. Transplant recipients with
microbiologically proven pH1N1 infection in 2009/2010 underwent humoral and cell-mediated immunity (CMI) testing
for pH1N1 just prior to the next influenza season. Concurrent testing for A/Brisbane/59/2007 was done to rule-out cross-
reacting antibody. We enrolled 22 adult transplant patients after pH1N1 infection. Follow up testing was done at a median
of 7.4 months (range 5.8–15.4) after infection. After excluding those with cross-reactive antibody, 7/19 (36.8%) patients were
seroprotected. Detectable pH1N1-specific CD4+ and CD8+ interferon-c producing T-cells were found in 11/22 (50%) and 8/
22 (36.4%) patients respectively. Humoral immunity had a significant correlation with a CD4 response. This is the first study
in transplant patients to evaluate long-term humoral and cellular response after natural influenza infection. We show that a
substantial proportion of SOT recipients with previous pH1N1 infection lack long-term humoral and cellular immune
responses to pH1N1. These patients most likely are at risk for re-infection.
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Introduction
Pandemic influenza A/H1N1 (pH1N1) caused widespread
infection in 2009 and early 2010 creating a spectrum of disease
in organ transplant recipients with a mortality rate of up to 7.8%
[1–3]. An important clinical question in transplant patients who
were infected with pH1N1 during the initial pandemic was
whether they would be at risk for re-infection with pH1N1 in the
subsequent influenza season. Humoral and cellular responses to
influenza infection are likely important in determining disease
severity and recovery from infection. The humoral response to
influenza includes the development of neutralizing antibodies
against the surface glycoprotein, hemagglutinin. This antibody
response is seen at 4 to 7 weeks post-infection and declines slowly
afterwards. One study showed a 100% seroconversion rate to
pH1N1 infection in healthy 14 to 20 year olds by day 30 post-
infection. Antibody titers were present in only 52% of patients by
day 180 [4]. Although the antibody response is very important in
subsequent protection against infection, CD4+ and CD8+ T-cell
responses also play a role [5,6]. Cytotoxic T lymphocyte (CTL)
response to influenza has been shown to peak at 14 days post
infection in immunocompetent individuals [5]. A CTL response is
directed towards the internal conserved proteins of the virus and
reduces the severity of disease although has not been shown to
prevent disease. CD8+ T cell response has correlated with
reductions in the duration and level of virus replication in adults
who have a history of low levels of antibodies that are then
challenged with seasonal influenza A. However, this cellular
immunity has been shown to diminish over years [7]. Critically ill
patients with pH1N1 have also demonstrated strong interferonc,
T-helper (Th) 1 and Th17 response to infection early in the course
of illness although the long-term sustainability of these responses is
not known [8].
It is also unknown if organ transplant recipients are able to
produce similar humoral and cellular responses to pH1N1
infection compared to immunocompetent persons. Equally, it
is unknown whether transplant recipients that recover from
influenza infection retain a long-term humoral response or
have a robust cellular response if rechallenged with the same
viral subtype. Seasonal influenza vaccine responses in trans-
plant recipients are known to be suboptimal. Monovalent
pandemic vaccine responses in transplant recipients have been
shown to be similarly low [9]. Therefore, similar to vaccina-
tion, we hypothesized that transplant recipients would have
poor long-term immunity to natural influenza infection and
would therefore be at risk of being re-infected with the same
strain during the next influenza season. The purpose of our
study was to determine whether organ transplant recipients
retain specific immunity to pH1N1 several months after
infection.
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Patient population
This study was approved by the institutional Ethics Review
Board. All patients provided informed consent. Adult organ
transplant recipients seen at the University of Alberta Hospital,
Edmonton, were prospectively enrolled in the study if they had
microbiologically proven pH1N1 during 2009–2010. All influen-
za A positive specimens were confirmed as pH1N1 by PCR.
Serum and peripheral blood mononuclear cells (PBMCs) were
collected from each patient prior to the onset of the next
influenza season (2010–2011 season). Clinical information
collected included demographic data, hospitalization due to the
original pH1N1 infection, treatment of infection, and type of
immunosuppression.
Laboratory Methods
Serum and PBMCs were collected from transplant recipients
with previous pH1N1 infection. Sera were stored at 280uCa n d
underwent a hemagglutination inhibition assay (HAI) at the
Ontario Agency for Health Protection and Promotion,
Toronto, Ontario using a previously described method [10].
Sera underwent HAI for A/California/7/2009 and for A/
Brisbane/59/07 to rule out cross-reactive H1N1 antibody. The
HAI assay was performed with 0.7% guinea pig erythrocytes
and 4 HA units of virus. Sera were tested at an initial dilution of
1:10 and a final dilution of 1:1280. PBMCs were isolated from
whole blood using Ficoll-Paque Premium (Pharmacia, Uppsala,
Sweden) gradient density centrifugation and stored in liquid
nitrogen till use. To measure intracellular IFNc responses from
pH1N1-specific T-cells, PBMCs were thawed, then incubated
for 16 hours at 37uCi n5 %C O 2, counted and adjusted to a
concentration of 1610
6 cells per 400 mL. The samples were
then stimulated for 24 hours with live pH1N1 virus (A/
California/4/2009; Advanced Biotechnologies Inc., Columbia,
MD) using a multiplicity of infection (MOI) of 0.5 and 1610
6
cells per reaction. Anti-CD3 (10 mg/mL) was used as the
positive control; media alone served as the negative control.
Brefeldin A was added 2 hours after stimulation to halt further
interferonc (IFNc)s e c r e t i o n .U s i n gf l u o rescent monoclonal
antibodies (eBioscience Inc., San Diego, CA), the cells were
surface stained for CD4 and CD8 with anti-human CD4 (PE-
Cy7) and anti-human CD8 (APC-eFluor 780) respectively.
After fixation, PBMCs were stained for intracellular interferonc
with PE. The percentage of pH1N1-specific CD4+ and CD8+
T cells producing interferonc was determined using flow
c y t o m e t r y[ 1 1 ] .T h ef l o wd a t aw e r ea c q u i r e du s i n ga
FACSCanto instrument equipped with FACSDIVA software
and the results were analyzed by FCS Express Version 3 (from
De Novo Software). 50,000 lymphocyte gate events were
obtained per single sample. Isotype control antibodies and
negative control samples were used to define the amount of non
responsive T-cells. Prior to testing patient samples, the protocol
was validated using a) PBMCs from non-transplanted persons
who were vaccinated or had microbiologically-confirmed
pH1N1 during 2009–2010 (positive controls for the method);
and b) PBMCs from healthy volunteers stored during 2008
prior to the onset of pH1N1. These served as negative controls
for the CMI protocol. In 16 healthy individuals either
vaccinated or with previous pH1N1, the median CD4+ T-cell
frequency was 0.92% (range 0.35–3.2) and the median CD8+ T
cell frequency was 0.96% (range 0.33–2.43). This compared to
t h r e en e g a t i v ec o n t r o l sw i t hm e d i a nC D 4 + and CD8+ Tc e l l
frequency of 0.03% and 0.04% respectively.
Definitions in the study
For the humoral response post-infection, seroprotection was
defined as a strain-specific antibody titer $1:40 [12]. A/Brisbane/
59/2007 (also an H1N1 virus) is a seasonal strain used in the
annual trivalent influenza vaccine for 2009–2010. Since influenza
A/Brisbane may result in cross-reactive antibody to pH1N1, if
sera also showed a titer $1:40 to influenza A/Brisbane,
seroprotection was only considered if pH1N1 antibody titer was
4-fold greater than A/Brisbane titer (even though patients may
also have seroprotective levels to pH1N1). For the pH1N1-specific
cellular immune response post-infection, CD4+ IFNc production
was calculated by dividing the number of CD4+ cells producing
IFNc by the total number of CD4+ T-cells. The same calculation
was done for CD8+ IFNc production. A positive pH1N1 specific
CD4 or CD8 IFNc response was defined as $2 standard
deviations above the mean of the negative control for each sample
and greater than 0.2%.
Statistics
Statistical analysis was performed using SPSS (version 18.0;
SPSS) and GraphPad Prism version 4.0. A univariate analysis was
performed to determine variables affecting humoral and cellular
responses. Correlations between humoral and cellular immunity
were assessed using linear regression.
Results
Patient population
During 2009–2010, 25 adult solid organ transplant recipients
had microbiologically proven pH1N1 at our center. Three patients
were lost to follow-up or did not provide consent for blood testing.
Therefore, we were able to enroll 22 adult patients for follow-up
blood prior to the 2010–2011 influenza season. Baseline
characteristics of the cohort are shown in Table 1. The four most
common types of transplants were lung (7/22; 31.8%), kidney (6/
22; 27.3%), heart (3/22; 13.6%), and liver (3/22; 13.6%). The
median time from transplantation to documented pH1N1
infection was 4.5 years (range 0.3 to 18.7). The most common
combination of immunosuppression used included mycophenolate
mofetil (MMF), calcineurin-inhibitor, and prednisone. Antiviral
therapy (oseltamivir) was given to 21/22 (95.5%) patients and 7/
22 (31.8%) patients required hospitalization. Only 2/22 (9.1%)
recipients required ICU admission while hospitalized. Six patients
had chest x-ray findings consistent with pneumonia during their
hospitalization. Following recovery from pH1N1 infection,
patients were told by their transplant teams they should not
receive the monovalent pH1N1 vaccine as they had already had
resolved natural infection. However, three patients received the
monovalent pH1N1 vaccine during 2009/2010 influenza season
and of these, two were immunized prior to infection and only one
patient was immunized within one week of resolved infection. For
seasonal vaccination, patients were encouraged to receive the
2009/2010 seasonal trivalent vaccine. At the time of testing, no
patient had yet received annual influenza vaccine for the 2010–
2011 season.
Humoral Response
The median time from natural infection to assessment of
humoral immune resonse was 7.4 months (range 5.8 to 15.4). Of
the cohort, 10/22 (45.5%) patients met the criteria for long-term
seroprotection to pH1N1 ($1:40 antibody titer). In 5/22 cases,
patients also had cross-reactive antibody to A/Brisbane. In three
cases, pH1N1 antibody titers did not exceed A/Brisbane titers by
$4-fold; therefore, these results were considered indeterminate
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(36.8%) patients were confirmed seroprotected for pH1N1. In
these 7 patients, the median titer was 1:160 (range 1:40 to 1:640).
Patients hospitalized for pH1N1 were more likely to have a long-
term seroresponse 4/5 (80%) than those not admitted to hospital
3/14 (21.4%); p=0.038. Thoracic (heart and lung) transplant
recipients had a trend towards a lack of long-term humoral
response to pH1N1 infection compared to other SOT recipients
(11.1% vs. 60.0%; p=0.057). Shorter time to follow up of
serologic measurement after infection was associated with a higher
likelihood of seroprotection (7.562.2 months in responders vs.
9.162.6 months in non-responders, p=0.047). For patients who
were measured between 5–8 months post-infection, the seropos-
itivity rate was 50% (6/12); for those measured between 8–12
months (seropositivity was 0% (0/5)) and for those between 13–15
months (seropositivity was 50% (1/2)). Factors that were not
associated with a sustained humoral response included time from
transplant, type of immunosuppression or calcineurin-inhibitor
levels, early versus late antiviral treatment, presence or absence of
lymphopenia and history of previous seasonal influenza vaccina-
tion. Of the three patients that were also immunized for pH1N1,
only one had sustained seroprotection.
Cell Mediated Immunity (CMI)
Similar to the antibody assessment, the median time from
infection to assessment of CMI was 7.4 months. All 22 patient
PBMCs underwent flow cytometry analysis for pH1N1-specific
IFNc production from CD4+ and CD8+ T cells. The range of
pH1N1 specific T cell frequencies is shown in Figure 1. The
median CD4+IFNc frequency was 0.32% (range 0.07%–2.1%).
For CD8+ T cells, median frequency of positive cells was 0.14%
(range 0.01%–1.2%). Figure 2 shows representative flow analysis
for three patients. Patient 1 had both a humoral and CMI
response to past infection whereas patient 2 had only a humoral
response, and patient 3 had no humoral or CMI response.
Overall, 11/22 (50%) and 8/22 (36.4%) patients had a positive
pH1N1-specific CD4+ and CD8+ T cell response respectively. A
CD4+ IFNc response was present in 3/7 (42.9%) of seroprotected
patients but also 7/12 (58.3%) patients who had negative serology
(p=NS). Similarly, a CD8+ IFNc response was present in 6/7
(85.7%) of seroprotected patients and 9/12 (75%) of patients with
negative serology (p=NS). Four of 19 patients (21.1%) were
negative for all three immunological parameters. The three
patients with indeterminate serology (i.e. cross-reactive antibody
to A/Brisbane) had a CMI response in 1 of 3 patients for CD4 and
2 of 3 patients for CD8. Of the three patients that were immunized
for pH1N1, only one had a persisting CD4+IFNc and CD8+IFNc
response at the time of follow-up.
The CD4+ T cell response had a significant association with
pH1N1 antibody titer; R
2=0.428, p=0.002 (Figure 3). Tacroli-
mus trough levels were inversely correlated with frequencies of
CD4+IFNc T-cells, i.e, CD4+IFNc T-cell frequencies were higher
in patients with lower tacrolimus trough levels (R
2=0.442,
p=0.007). No other correlations with immunosuppression were
observed. There was no significant correlation between
CD4+IFNc or CD8+IFNc frequency of T cell specific cells and
the presence of lymphopenia, time from transplant to infection or
the use of early antiviral therapy. In addition, hospitalization at the
time of natural infection was not predictive of a T-cell response.
Discussion
We determined the long-term humoral and cellular immune
responses in 22 adult transplant patients who recovered from
pH1N1 infection. We found that only approximately one-third of
our cohort had a sustained humoral response. Cellular responses
were present in a similar proportion of patients (50% CD4 and
36.4% CD8) and a significant proportion of patients had an
absence of both humoral and cellular (CD4, and CD8) responses
(21.1%). Our results suggest that even after natural pH1N1
Table 1. Baseline characteristics of cohort with
microbiologically proven pandemic influenza A/H1N1 during
2009/2010.
Characteristic N=22 (%)
Gender (M/F) 14/8
Median age (years) 55.5 (range 26–71)
Type of Transplant
Lung 7 (31.8%)
Kidney 6 (27.3%)
Heart 3 (13.6%)
Liver 3 (13.6%)
Other (Combination or Islet) 3 (13.6%)
Time from Transplant to Infection
(median and range)
4.5 years
(range 0.3–18.7)
Time from Infection to Follow-up
Testing (median and range)
7.4 months
(range 5.8–15.4)
Immunosuppression
MMF 19 (86.4%)
Calcineurin-inhibitor 19 (86.4%)
Prednisone 16 (72.7%)
Sirolimus 1 (4.5%)
Azathioprine 1 (4.5%)
Everolimus 1 (4.5%)
doi:10.1371/journal.pone.0028627.t001
Figure 1. Range of pH1N1-specific CD4+IFNc+ and CD8+IFNc+ T
cell frequencies (%) in peripheral blood mononuclear cells of
individual patients (n=22). Samples taken after natural pH1N1
infection but prior to the onset of the next influenza season. Horizontal
line represents median response.
doi:10.1371/journal.pone.0028627.g001
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risk for re-infection with the same strain in subsequent influenza
seasons. To our knowledge, this is the first study examining the
long-term responses to natural influenza infection in solid organ
transplant recipients.
Another study looked at humoral and cellular immunity to
pH1N1 in patients following hematopoietic stem cell transplanta-
tion. Only short-term immunological responses were evaluated
(within 12 weeks of infection); the authors found that only 6/11
(54.5%) patients had a humoral response compared to 100% of
controls and that H1N1-specific T cells could be measured in only
2/8 (25%) patients compared to 4/4 in the control group [13]. A
single study has looked at the humoral response to infection in a
cohort of immunocompetent patients infected with pH1N1. This
study found a 100% seroconversion rate by day 30 in young adults
but a rapid decline in titers to 52% by day 180 [4]. The decrease
in titers over time is also shown in our study where the percentage
of seroprotected patients was lower with increasing time post-
infection. Our seropositivity rate at around the six month time
point was quite similar to that shown by Wang et al.
Cellular immune responses to pandemic H1N1 infection have
previously been described in immunocompetent patients by
Bermejo-Martin et al. IL-8, IFNc, IL-13, IL-10 were significantly
higher in hospitalized patients vs. outpatients and controls. While
both critical and non-critically hospitalized patients showed higher
levels of IL-17 and TNFa than controls, only severe critically ill
patients had significantly elevated levels of IL-17 and TNFa [8]. In
the current study, we did not measure the cellular response at the
time of infection but did find that hospitalized patients did not
have a greater long-term cellular response. In transplant
recipients, cellular responses have been investigated after vacci-
nation but not after infection. For example, Mazzone et al.
evaluated CMI in 43 lung transplant recipients and in 21 healthy
controls after influenza vaccination. IL-2, IL-10, IFNc, and
granzyme B levels did not rise from pre- to post-vaccination in the
lung transplant group and were overall lower in the transplant
group when compared to the control group [14].
We also found that the ten heart and lung transplant recipients
tended to have lower cellular responses to influenza infection
compared with other types of transplant. This may reflect a higher
net state of immunosuppression and is similar to that seen in
influenza vaccine studies that suggest poor vaccine immunogenicity
in lung transplant recipients compared to kidney recipients [15,16].
In our study, higher tacrolimus levels were associated with a lower
CD4+ T cell response although this was not the case for CD8
responses. We also found a significant association between CD4+ T
cell response and the humoral response. In contrast, no correlation
between cellular and humoral immunity has been found in studies of
transplant patients who received seasonal influenza vaccine [17].
One limitation of our study is the small number of patients
tested; to carry out similar studies in larger number of transplant
patients with natural influenza infection, a multicenter approach
would likely be needed. We did not do pre-infection testing or
testing at earlier time points post-infection; however, similar to
seroprevalence studies, we did serology for A/Brisbane to rule out
cross-reactive H1N1 antibodies. We were also able to show
diminished long-term response which is important when consid-
ering a revaccination strategy for subsequent annual vaccination.
However, our findings represent an immune response to the
infecting strain and not to significantly shifted influenza strains.
Although the decline in humoral immunity shown in our study
is similar to that shown by Wang et al. in the immunocompetent
population, we believe this is of significant concern in the
immunocompromised transplant patient. From previous literature,
transplant patients are more likely to have a poor outcome from
influenza infection and more likely to have greater tissue viral
loads and prolonged shedding times [1,18]. Preventative strategies
for re-infection include vaccination, antiviral prophylaxis, and
safe-living strategies to avoid potential exposures. The immuno-
genicity of trivalent inactivated influenza vaccine after transplan-
tation is quite variable and seroprotection post-vaccination ranges
from 28–93% [9,16]. In our study, the two patients that received
pH1N1 vaccine after infection did not have a long-term response.
Strategies such as giving two or three doses of influenza vaccine
during the season have not been shown to significantly increase
immunogenicity [16,19]. Giving low-dose intradermal vaccine also
did not improve responses in a cohort of lung transplant recipients
[15]. Another strategy may be to provide chemoprophylaxis to all
or a select group of transplant recipients during the influenza
season. The cost-effectiveness, drug interactions, medication
compliance and risk of antiviral resistance with this strategy would
have to be considered. In summary, this study provides novel
evidence that the majority of transplant patients with previous
pH1N1 infection likely remain at risk for re-infection and are
candidates for future prevention strategies.
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Figure 2. Representative flow cytometry plots for 3 individual patients. A) Patient 1: pH1N1 antibody titer of 1:640, CD4+/IFNc frequency of
1.78% (positive), and CD8+/IFNc frequency of 0.57% (positive); B) Patient 2: pH1N1 antibody titer of 1:80, CD4+/IFNc frequency of 0.25% (negative),
and CD8+/IFNc frequency of 0.13% (negative); C) Patient 3: Negative serology, CD4+/IFNc frequency of 0.07% (negative) and CD8+/IFNc frequency of
0.07% (negative).
doi:10.1371/journal.pone.0028627.g002
Figure 3. Relationship between CD4+IFNc T-cell frequency (%)
and the humoral response (n=19). (R
2=0.428, P=0.002).
doi:10.1371/journal.pone.0028627.g003
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